Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTX-6058 Phase 1 Safety and PK Study in Healthy Adults and SCD
NCT04586985Phase 1Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pociredir in sickle cell disease (SCD) (5 arms), sponsored by Fulcrum Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 4 weeks. Started Oct 2020; status: completed.
02
Drugs
pociredir
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04586985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586985.